Meeder Asset Management Inc Eloxx Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $7.2 $5,857 - $281,145	-39,048 Reduced 98.42%	627 $0
Q2 2022 Aug 08, 2022	BUY	$0.24 - $0.58 $2,674 - $6,463	11,144 Added 39.06%	39,675 $10,000
Q1 2022 May 10, 2022	BUY	$0.4 - $0.72 $11,412 - $20,542	28,531 New	28,531 $16,000
Q4 2021 Feb 11, 2022	SELL	$0.62 - $1.61 $15,982 - $41,502	-25,778 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$1.22 - $2.0 $6,491 - $10,642	5,321 Added 26.01%	25,778 $41,000
Q2 2021 Aug 09, 2021	BUY	$1.35 - $3.36 $19,549 - $48,656	14,481 Added 242.32%	20,457 $41,000
Q1 2021 Apr 28, 2021	BUY	$3.02 - $4.54 $18,047 - $27,131	5,976 New	5,976 $19,000
Q4 2020 Feb 09, 2021	SELL	$2.42 - $4.48 $3,910 - $7,239	-1,616 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$1.56 - $3.65 $1,386 - $3,244	889 Added 122.28%	1,616 $5,000
Q1 2020 May 15, 2020	SELL	$1.96 - $7.96 $987 - $4,011	-504 Reduced 40.94%	727 $1,000
Q4 2019 Feb 13, 2020	BUY	$3.19 - $7.56 $2,201 - $5,216	690 Added 127.54%	1,231 $9,000
Q2 2019 Aug 05, 2019	BUY	$8.77 - $12.49 $4,744 - $6,757	541 New	541 $5,000

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.